Archive · 3 Nov 2025
Dilbert Creator Scott Adams Asks Trump for Help Securing Cancer Treatment
Scott Adams, who created the Dilbert comic strip, is very sick with prostate cancer that has spread.
He needs a special medicine called Pluvicto, which is like a targeted therapy that helps fight cancer cells.
The medicine was approved, and his doctor said he could have it.
But, Adams says the place that gives him the medicine, Kaiser Permanente, has not scheduled his treatment, and he is getting worse quickly.
He asked President Donald Trump for help because Trump had previously offered to help him if he ever needed it.
Adams hopes Trump can get Kaiser to schedule his treatment so he can have a chance to get better.
Trump and his family have responded, saying they are looking into it to help him.
Dilbert creator Scott Adams has publicly asked former President Donald Trump for assistance.
Adams is seeking help to expedite the scheduling of a new cancer drug, Pluvicto, for his advanced prostate cancer.
He alleges that his healthcare provider, Kaiser Permanente of Northern California, has failed to schedule the IV administration of the drug.
Pluvicto, approved by the FDA in 2022, is a radioligand therapy for metastatic prostate cancer.
President Trump and members of his family have responded, indicating they are working to help Adams.
- Who
- Scott Adams, creator of the Dilbert comic strip
- What
- Appealed to Donald Trump for help in securing timely administration of a new cancer drug, Pluvicto, due to alleged scheduling issues with his healthcare provider.
- When
- Sunday (post on X), seeking help for administration on Monday.
- Where
- Post on X (formerly Twitter), with the issue concerning Kaiser Permanente of Northern California.
- Why
- Adams is suffering from advanced, metastasized prostate cancer and is reportedly declining fast, struggling to get his approved treatment scheduled.
- Who
- Scott Adams, creator of the Dilbert comic strip
- Condition
- Advanced prostate cancer
- Requested Treatment
- Pluvicto (Lutetium Lu 177 vipivotide tetraxetan)
- Healthcare Provider
- Kaiser Permanente of Northern California
- Drug Approval Year
- 2022